sorafenib has been researched along with isocorydine in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (isocorydine) | Trials (isocorydine) | Recent Studies (post-2010) (isocorydine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 49 | 0 | 22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di, D; Han, Y; Li, R; Li, W; Liu, J; Xin, A; Yan, Q; Zhang, Y | 1 |
| Chen, L; Chen, T; Cui, Y; Fang, T; Ge, C; Jiang, G; Li, H; Li, J; Li, M; Liu, J; Tian, H; Xie, H; Yao, M; Zhang, L | 1 |
| Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F | 1 |
3 other study(ies) available for sorafenib and isocorydine
| Article | Year |
|---|---|
Design, synthesis, and anticancer properties of isocorydine derivatives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aporphines; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship | 2017 |
An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Topics: AC133 Antigen; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Aporphines; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Peptides; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA-Binding Proteins; Sorafenib; Survival Analysis; Time Factors; Transfection | 2015 |
Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aporphines; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-beta; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Female; G2 Phase Cell Cycle Checkpoints; Humans; Liver Neoplasms; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |